Dr. Oppelt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4921 Parkview Pl
# Dv
Saint Louis, MO 63110Phone+1 800-647-2098Fax+1 314-362-3192
Education & Training
- Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematology and Medical Oncology, 2012 - 2015
- Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 2008 - 2012
- University of Missouri-Columbia School of MedicineClass of 2008
Certifications & Licensure
- IL State Medical License 2020 - 2026
- MO State Medical License 2015 - 2026
- OH State Medical License 2008 - 2016
Clinical Trials
Publications & Presentations
PubMed
- 2 citationsPembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV...Marcin Dzienis, Juan Cundom, Christian Sebastian Fuentes, Anna Spreafico, Melanie Nordlinger
Journal of Clinical Oncology. 2024-09-01 - 1 citationsRamucirumab in combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma: a single-centre, phase 1/2 trial.Douglas Adkins, Jessica C Ley, Jingxia Liu, Peter Oppelt
The Lancet. Oncology. 2024-07-01 - Trends in ototoxicity monitoring among cisplatin-treated patients with cancer.David S Lee, Emma Y Travis, Susan K Wong, Marie-Ange Munyemana, Lauren Mueller
Journal of Cancer Survivorship. 2024-04-17
Journal Articles
- Outcomes of Patients with Single-Node Metastasis of Human Papillomavirus–Related Oropharyngeal Cancer Treated with Transoral SurgeryPeter Oppelt, Kevin Palka, JAMA Otolaryngology–Head & Neck Surgery
Press Mentions
- Safety and Efficacy of Zimberelimab (AB122) in Combination with Domvanalimab (AB154) and Etrumadenant (AB928) in Patients with Previously Treated Non-Small Cell Lung CancerMarch 10th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: